Prevail Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch PRVL and buy or sell other stocks, ETFs, and their options commission-free!About PRVL
Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson's disease and other neurodegenerative diseases.
CEOFranz F. Hefti, PhD
CEOFranz F. Hefti, PhD
Employees—
Employees—
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2017
Founded2017
Employees—
Employees—
PRVL Key Statistics
Market cap787.70M
Market cap787.70M
Price-Earnings ratio-10.03
Price-Earnings ratio-10.03
Dividend yield—
Dividend yield—
Average volume1.19M
Average volume1.19M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$23.35
52 Week high$23.35
52 Week low$9.02
52 Week low$9.02
Stock Snapshot
Prevail Therapeutics(PRVL) stock is priced at $23.00, giving the company a market capitalization of 787.7M. It carries a P/E multiple of -10.03.
On 2025-12-13, Prevail Therapeutics(PRVL) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 1.19M.
Over the past 52 weeks, Prevail Therapeutics(PRVL) stock has traded between a high of $23.35 and a low of $9.02.
Over the past 52 weeks, Prevail Therapeutics(PRVL) stock has traded between a high of $23.35 and a low of $9.02.
People also own
Based on the portfolios of people who own PRVL. This list is generated using Robinhood data, and it’s not a recommendation.